Zydus receives approval from Health Canada for Mesalamine suppositories

Zydus Lifesciences Limited (including its subsidiaries/ affiliates, hereafter referred to as "Zydus") has received NOC (Notice of Compliance) from Health Canada for generic Mesalamine suppositories 1000 mg.

Mesalamine suppositories are indicated for the treatment of mildly to moderately active ulcerative proctitis.

ZDS - Mesalamine suppositories will be manufactured at Zydus Lifesciences Ltd. Changodar, Ahmedabad in Gujarat, India. Mesalamine suppositories had annual sales of 4.86 mn CAD (Canadian Dollars) in Canada (IQVIA MAT June 2025).

Shares of Zydus Lifesciences Limited was last trading in BSE at Rs. 1005.65 as compared to the previous close of Rs. 1007.80. The total number of shares traded during the day was 13215 in over 945 trades.

The stock hit an intraday high of Rs. 1008.95 and intraday low of 991.80. The net turnover during the day was Rs. 13224346.00.

Source : Equity Bulls

Keywords

ZydusLifesciences INE010B01027 Pharmaceuticals HealthCanada Approval MesalamineSuppositories